Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by WESCAP Management Group Inc.

WESCAP Management Group Inc. reduced its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,730 shares of the company’s stock after selling 162 shares during the period. WESCAP Management Group Inc.’s holdings in Prestige Consumer Healthcare were worth $1,463,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Cerity Partners LLC increased its stake in Prestige Consumer Healthcare by 103.9% during the third quarter. Cerity Partners LLC now owns 6,347 shares of the company’s stock worth $458,000 after acquiring an additional 3,234 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Prestige Consumer Healthcare by 276.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,379 shares of the company’s stock worth $1,253,000 after purchasing an additional 12,759 shares during the last quarter. Paloma Partners Management Co purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at about $274,000. HighTower Advisors LLC lifted its position in Prestige Consumer Healthcare by 4.9% in the third quarter. HighTower Advisors LLC now owns 16,708 shares of the company’s stock valued at $1,215,000 after buying an additional 774 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in Prestige Consumer Healthcare by 13.7% during the third quarter. Stifel Financial Corp now owns 19,299 shares of the company’s stock worth $1,391,000 after buying an additional 2,322 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Trading Down 0.1 %

NYSE:PBH opened at $85.93 on Wednesday. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The firm has a market cap of $4.26 billion, a PE ratio of 20.12, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The stock has a fifty day moving average price of $83.58 and a 200 day moving average price of $79.25.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PBH shares. Canaccord Genuity Group upped their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Oppenheimer upped their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Royal Bank of Canada lifted their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a research note on Friday, March 21st. DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.